Nephros raises $5m in private money:
This article was originally published in Clinica
New York-based renal disease therapy company Nephros has raised $5m following the sale of secured convertible notes to several investors. The proceeds will be used to fund product development and marketing and to provide working capital for commercialising its new water filtration technology. The company develops dialysis devices for patients suffering from end-stage renal disease; its latest water filtration device is designed to remove a broad range of bacteria, viral agents and toxic substances including - among others - salmonella, HIV, hepatitis and E coli.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.